Louis Lehot on Biotech IPOs – 'Biotech could have a great fourth quarter'
September 4, 2024
Bloomberg Law
Foley & Lardner LLP partner Louis Lehot offered insight on the biotech industry’s upcoming initial public offerings in the Bloomberg Law article, “Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch.”
“Biotech could have a great fourth quarter, we have a great pipeline,” Lehot commented, as several biotech companies look to reignite the sector with upcoming IPOs. “Biotech IPOs are here and ready to put money to work.”
(Subscription required)
People
Related News
March 13, 2026
In the News
Chris Babcock and Chris Converse on Wave of Companies Moving to Texas
Foley & Lardner LLP partners Chrisopher Babcock and Chris Converse commented on the widening trend of companies reincorporating to Texas in the Houston Business Journal article, “Texas law changes could spark wave of corporate redomestication proposals."
March 12, 2026
In the News
Louis Lehot Explores M&A's Growing Blitzhire Phenomenon
Foley & Lardner LLP partner Louis Lehot authors article on the emergence of blitzhires in the Mergers & Acquisitions article, “Blitzhires: The New Fast-Moving M&A Deal.”
March 10, 2026
In the News
Aaron Maguregui Shares Insights on Shadow AI Risks in Health Care
Foley & Lardner LLP partner Aaron Maguregui was quoted in the Part B News article, “Do you need AI policy? Experts suggest guardrails as 'shadow AI' spreads,” discussing the emerging risks of unsanctioned 'shadow AI' use by clinicians and the need to establish robust AI governance.